143 related articles for article (PubMed ID: 7463350)
1. Pharmacokinetics and bioavailability of acyclovir in the dog.
Krasny HC; de Miranda P; Blum MR; Elion GB
J Pharmacol Exp Ther; 1981 Feb; 216(2):281-8. PubMed ID: 7463350
[TBL] [Abstract][Full Text] [Related]
2. The disposition of acyclovir in different species.
de Miranda P; Krasny HC; Page DA; Elion GB
J Pharmacol Exp Ther; 1981 Nov; 219(2):309-15. PubMed ID: 7288622
[TBL] [Abstract][Full Text] [Related]
3. Species differences in the disposition of acyclovir.
de Miranda P; Krasny HC; Page DA; Elion GB
Am J Med; 1982 Jul; 73(1A):31-5. PubMed ID: 7102710
[TBL] [Abstract][Full Text] [Related]
4. Disposition in the dog and the rat of 2, 6-diamino-9-(2-hydroxyethoxymethyl)purine (A134U), a potential prodrug of acyclovir.
Good SS; Krasny HC; Elion GB; de Miranda P
J Pharmacol Exp Ther; 1983 Dec; 227(3):644-51. PubMed ID: 6655561
[TBL] [Abstract][Full Text] [Related]
5. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
6. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
Halpin RA; Geer LA; Zhang KE; Marks TM; Dean DC; Jones AN; Melillo D; Doss G; Vyas KP
Drug Metab Dispos; 2000 Oct; 28(10):1244-54. PubMed ID: 10997947
[TBL] [Abstract][Full Text] [Related]
7. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
8. Disposition and metabolism of finasteride in dogs.
Carlin JR; Christofalo P; Arison BH; Ellsworth RE; Rosegay A; Miller RR; Chiu SH; VandenHeuvel WJ
Drug Metab Dispos; 1997 Jan; 25(1):100-9. PubMed ID: 9010636
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in the dog.
Shukla UA; Marathe PH; Pittman KA; Barbhaiya RH
Drug Metab Dispos; 1993; 21(3):502-7. PubMed ID: 8100508
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical pharmacokinetics of the cyclooxygenase-inhibiting nitric oxide donor (CINOD) AZD3582.
Fagerholm U; Breuer O; Swedmark S; Hoogstraate J
J Pharm Pharmacol; 2005 May; 57(5):587-97. PubMed ID: 15901348
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
13. Absorption, disposition, and metabolism of [14C]didanosine in the beagle dog.
Kaul S; Shyu WC; Shukla UA; Dandekar KA; Barbhaiya RH
Drug Metab Dispos; 1993; 21(3):447-53. PubMed ID: 8100500
[TBL] [Abstract][Full Text] [Related]
14. Metabolic fate and pharmacokinetics of the acyclovir prodrug valaciclovir in cynomolgus monkeys.
de Miranda P; Burnette TC
Drug Metab Dispos; 1994; 22(1):55-9. PubMed ID: 8149890
[TBL] [Abstract][Full Text] [Related]
15. Interaction between valproic acid and acyclovir after intravenous and oral administration in a rabbit model.
van Jaarsveld MF; Walubo A; du Plessis JB
Basic Clin Pharmacol Toxicol; 2007 Dec; 101(6):434-40. PubMed ID: 18028106
[TBL] [Abstract][Full Text] [Related]
16. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
17. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of N-nitrosodimethylamine in beagles.
Gombar CT; Pylypiw HM; Harrington GW
Cancer Res; 1987 Jan; 47(2):343-7. PubMed ID: 3791224
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs.
Usui T; Watanabe T; Higuchi S
Drug Metab Dispos; 1995 Nov; 23(11):1214-9. PubMed ID: 8591721
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]